Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corporation reports developments tied to blood volume measurement technology, including commercialization of its FDA-cleared Blood Volume Analysis diagnostics and the BVA-100 Blood Volume Analyzer. Company news commonly covers clinical data, cardiology and critical-care use cases, new customer programs, conference presentations, and product updates for rapid, portable BVA systems.
Daxor also issues updates on financial results, shareholder communications, capital actions, and market expansion for its ezBVA Lab workflow and related diagnostic services. Its coverage centers on precision fluid management, heart failure, ICU care, and adoption of direct blood, plasma, and red-cell volume measurement in clinical settings.
Daxor Corporation (NYSE: DXR) has announced a Cooperative Research and Development Agreement with The Uniformed Services University and The Henry M. Jackson Foundation to research its BVA-100 diagnostic test for measuring circulatory blood volume in traumatic injuries. CEO Michael Feldschuh emphasized the BVA-100's potential to enhance battlefield resuscitation practices by providing precise blood volume measurements, improving survival rates. This partnership focuses on critical conditions like hemorrhage and trauma, and aims to translate military advancements to civilian care.
Daxor Corporation (DXR) announced a registered direct offering involving 125,000 shares of common stock from the Company and 225,000 shares from the Estate of Joseph Feldschuh at $20.00 per share, generating gross proceeds of $7.0 million. The Company plans to allocate $2.5 million for working capital and corporate purposes. The offering is set to close around July 22, 2020. H.C. Wainwright & Co. is the exclusive placement agent.
Daxor Corporation (NYSE: DXR) has initiated a multicenter study at NYU Langone Health to utilize its BVA-100 blood volume analysis technology in hospitalized COVID-19 patients. The trial aims to assess volume derangements in these patients to enhance care and outcomes. The BVA technology is noted for its precise volume measurement capabilities, which could lead to individualized treatment and improved prognostic assessments. Previous studies have indicated that BVA-guided care may significantly lower mortality rates in critical care settings.
Daxor Corporation (NYSE: DXR) announced that CEO Michael Feldschuh will participate in Maxim Group and M-Vest’s COVID-19 Virtual Series on May 27, 2020. He will be a panelist in the session titled “Cell Therapy For ARDS – When Remdesivir Is Not Enough.” This conference aims to address important medical discussions amidst the pandemic. Daxor specializes in blood volume measurement technology, including the FDA-cleared BVA-100, which improves treatment strategies in various medical conditions, ultimately enhancing patient outcomes.
Daxor Corporation (NYSE: DXR) announced the publication of blood volume outcome data in the journal Circulation, using its BVA-100 device in a Yale University study on heart failure. This study demonstrates the significant role of blood volume changes in improving long-term heart failure outcomes. CEO Michael Feldschuh emphasized the BVA-100's status as the gold standard for accurate blood volume measurement, confirming its relevance in both research and clinical settings. The study's findings support the efficacy of Empagliflozin in heart failure treatment.